Mettler-Toledo International (MTD) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
31 Jul, 2026Executive summary
Q2 2026 delivered strong results with reported sales up 4% to $1.03 billion and local currency sales up 6%, driven by robust organic growth in China and emerging markets, and supported by productivity and innovation initiatives.
Adjusted EPS for Q2 2026 was $11.46, up 14% year-over-year; reported EPS was $11.55, including a $0.92 net tariff refund benefit.
Operating results included a one-time $52.4 million benefit from U.S. government tariff refunds, partially offset by $27.8 million in customer refunds, impacting both cost of sales and net sales.
Segment profit rose, notably in China and the U.S., reflecting margin expansion and higher sales.
Strategic initiatives in sales, marketing, and productivity contributed to financial outperformance.
Financial highlights
Q2 2026 net sales reached $1.03 billion, up 4% year-over-year; adjusted gross margin was 59.3%, up 30 bps; gross margin including one-time items was 63.3%.
Adjusted operating profit was $309 million, up 9% year-over-year; adjusted operating margin was 29.3%, up 50 bps.
Adjusted EPS was $11.46, a 14% increase; six-month adjusted EPS was $20.35, up 11%.
Adjusted free cash flow YTD was $367 million; operating cash flow for the first half was $450.2 million.
Price realization for Q2 was ~3%; full-year price realization approaching 3%.
Outlook and guidance
Full-year 2026 local currency sales growth expected at 4–5% (excluding tariff refunds); organic growth of 3–4%.
Adjusted EPS guidance for 2026 raised to $47.15–$47.50, up 10–11%.
Q3 2026 local currency sales expected to grow ~4%; adjusted EPS guidance is $12.00–$12.15.
Free cash flow for 2026 expected at $900 million; share repurchases to increase to $875 million for the year.
Management expects continued growth, supported by investments in automation, digitalization, and onshoring trends.
Latest events from Mettler-Toledo International
- Q3 2025 delivered strong sales and EPS growth, with innovation and resilience amid tariff headwinds.MTD
Q3 20259 Jul 2026 - Q2 sales fell 4% but net earnings rose 4% and full-year EPS guidance was raised.MTD
Q2 20248 Jul 2026 - 2026 guidance targets 4% revenue growth, margin expansion, and full tariff mitigation.MTD
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Q4 2025 delivered 8% sales and EPS growth, with a strong outlook for 2026.MTD
Q4 20258 Jul 2026 - Strong Q1 growth, tariff mitigation, and margin initiatives position the business for resilience.MTD
Bank of America 2025 Healthcare Conference8 Jul 2026 - Q4 2024 saw double-digit sales and EPS growth, with 2025 guidance tempered by headwinds.MTD
Q4 20248 Jul 2026 - Q1 sales fell 5% to $883.7M, but margin gains and lab growth offset tariff headwinds.MTD
Q1 20258 Jul 2026 - Adjusted EPS up 9% and sales up 7% in Q1 2026, with raised full-year EPS guidance.MTD
Q1 202614 May 2026 - Strong earnings, innovation, and China-led growth support a positive second-half outlook.MTD
Bank of America Global Healthcare Conference 202613 May 2026